Effect Of Probiotic Lactobacillus Paracasei Lp-33 For The Management Of Rhinitis In People Sensitized To Allergens (BionAtlanta)
Evaluation of the Effect of Probiotic Lactobacillus Paracasei Lp-33 for the Management of Rhinitis in People Sensitized to Allergens. A Double Blind Randomized Parallel Placebo Controlled Study. (GA2LEN STUDY) BIONATLANTA Project
Sponsor: Merck Medication Familiale
A PHASE3 clinical study on Rhinitis, this trial is completed. The trial is conducted by Merck Medication Familiale and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Completed PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Apr 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Medication Familiale
- Novonesis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aix-en-Provence, France , Alès, France , Aubevoye, France , Aubord, France , Avoine, France , Beaucaire, France , Beauvoisin, France , Bischeim, France , Bompas, France , Bouillargues, France and 64 more locations